https://www.selleckchem.com/products/trolox.html
005 [stage III/IV] and P=0.004 [HGSC]; BRCA1/2 mutation P=0.03 [stage III/IV] and P0.001 [HGSC]). Patients with BRCA1/2-mutated cancers showed improved OS (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.43-0.99; P=0.045) and a trend toward improved PFI (HR, 0.48; 95% CI, 0.22-1.06; P=0.07) and PFS (HR, 0.72; 95% CI, 0.51-1.03; P=0.07). No survival differences were observed between BRCA1-methylated and BRCA1/2 wild-type non-BRCA1-methylated cancers. We observed a high tumor BRCA1/2 dysfunction rate in HGSC with a unique pred
Like
Comment
Share
